Group IVA cytosolic phospholipase A 2 (cPLA 2 α) is regulated by phosphorylation and calcium-induced translocation to membranes. Immortalized mouse lung fibroblasts lacking endogenous cPLA 2 α (IMLF -/-) were reconstituted with wild type and cPLA 2 α mutants to investigate how calcium, phosphorylation and the putative phosphatidylinositol 4,5-bisphosphate (PIP 2 ) binding site regulate translocation and arachidonic acid (AA) release. Agonists that elicit distinct modes of calcium mobilization were used. Serum induced cPLA 2 α translocation to Golgi within seconds that temporally paralleled the initial calcium transient. However, the subsequent influx of extracellular calcium was essential for stable binding of cPLA 2 α to Golgi and AA release. In contrast, phorbol myristate acetate induced low amplitude calcium oscillations, slower translocation of cPLA 2 α to Golgi and much less AA release, which were blocked by chelating extracellular calcium. AA release from IMLF -/-expressing phosphorylation site (S505A) and PIP 2 binding site (K488N/K543N/K544N) mutants was partially reduced compared to cells expressing wild type cPLA 2 α but calciuminduced translocation was not impaired. Consistent with these results, S505 phosphorylation did not change the calcium requirement for interfacial binding and catalysis in vitro, but increased activity by 2-fold. Mutations in basic residues in the catalytic domain of cPLA 2 α reduced activation by PIP 2 but did not effect the concentration of calcium required for interfacial binding or phospholipid hydrolysis. The results demonstrate that S505 phosphorylation and basic residues in catalytic domain principally act to regulate cPLA 2 α hydrolytic activity.
Group IVA cytosolic phospholipase A 2 (cPLA 2 α) specifically hydrolyzes arachidonic acid (AA) from the sn-2 position of membrane phospholipids in response to diverse cellular stimuli (1) (2) (3) (4) (5) . In releasing AA it performs a fundamental role in regulating signaling for a multitude of lipid mediated pathways that control many important cell processes. Leukotrienes and prostaglandins are products of AA metabolism via 5-lipoxygenase and cyclooxygenase pathways, respectively (6) . These metabolites regulate diverse processes in normal and diseased tissues making it important to tightly regulate the release of free AA through cPLA 2 α. cPLA 2 α is widely expressed in mammalian tissues reflecting its central role in regulating lipid mediator production in diverse cell types. cPLA 2 α is regulated posttranslationally by submicromolar levels of calcium and by phosphorylation (1, 2, 7) . Agonist-induced increase in the concentration of intracellular calcium ([Ca 2+ ] i ) leads to a loading of the C2 domain with calcium and this mediates cPLA 2 α translocation to Golgi, endoplasmic reticulum and nuclear envelope to access substrate (8) (9) (10) (11) (12) . cPLA 2 α has multiple phosphorylation sites in the catalytic domain. Analysis of cPLA 2 α expressed in baculovirus-infected Sf9 cells revealed constitutive phosphorylation of S454, S437 and S505, and phosphorylation on S727 in response to okadaic acid (13) . In mammalian cells cPLA 2 α is phosphorylated on S505, S727 and S515 by mitogen-activated protein kinases (MAPKs), MAPK-activated protein kinase MNK1 (or a related kinase), and calcium/calmodulin-dependant kinase II (CamKII), respectively (14) (15) (16) (17) (18) (19) . Phosphorylation of S505 and S727 are functionally important for regulating cPLA 2 α-mediated AA release from stimulated cells (14, 17) . It has recently been shown that phosphorylation of cPLA 2 α on S515 and S505 is required for AA release in vascular smooth muscle cells stimulated with norepinephrine (20) .
Phosphorylation of cPLA 2 α and physiological increases in [Ca 2+ ] i synergistically promote the full activation of cPLA 2 α for releasing AA (21) (22) (23) . Phosphorylation of cPLA 2 α on S505 increases its catalytic activity (14, 15, 24) , however the role of phosphorylation in regulating calciuminduced translocation in cells has not been resolved. It has been reported that phosphorylation of cPLA 2 α on S505 enhances the phospholipid binding affinity at low physiological calcium levels in vitro and in cells (25) . This is consistent with another study showing that the inability of cPLA 2 α phosphorylation site mutants to release AA is overcome by inducing supra-physiological [Ca 2+ ] i (17) . However, it has previously been shown that cPLA 2 α-S505A translocates to membrane in response to calcium ionophore although it releases less AA (26) . In addition, a direct comparison of wild type cPLA 2 α and phosphorylation site mutants by time-lapse imaging demonstrated similar translocation properties in response to physiological increases in calcium induced by ATP (27) .
Calcium binding to the cPLA 2 α C2 domain increases its affinity for membrane through hydrophobic interactions (28) (29) (30) (31) (32) . This positions the catalytic domain for interaction with the membrane by hydrophobic and electostatic mechanisms (33) . A tryptophan (W464) on the membrane binding face of the catalytic domain stabilizes cPLA 2 α and prolongs membrane binding after decreases in [Ca 2+ ] i (34) . A patch of basic residues (K488, K541, K543, K544) in the cPLA 2 α catalytic domain is the site of interaction with phosphatidylinositol-4,5-bisphosphate (PIP 2 ), which increases catalytic activity in vitro (33, (35) (36) (37) . However, the role of these basic residues in regulating translocation in cells stimulated with physiological agonists has not been investigated.
The goal of this study is to investigate the role of phosphorylation and basic residues in the catalytic domain in regulating cPLA 2 α. We compare the interfacial binding and kinetic properties of phosphorylated and mutant forms of cPLA 2 α in vitro as a function of calcium concentration with the behavior of these enzymes in a cellular reconstitution model. By expressing wild type and mutant forms of cPLA 2 α in lung fibroblasts lacking cPLA 2 α, we investigated the functional role of phosphorylation and the PIP 2 binding site in regulating calcium-dependent cPLA 2 α translocation and AA release without interference of endogenous wild type enzyme.
EXPERIMENTAL PROCEDURES

Materials
-1-Palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (PAPC), brain PIP 2 , (major species is 1-stearoyl-2-arachidonyl-PIP 2 ) and dipalmitoylsn-glycero-3-phosphoethanolamine-N-(Lissamine Rhodamine B sulfonyl) (ammonium salt) were from Avanti Polar Lipids. Electrospray ionization analysis of PIP 2 showed that it was not contaminated with dephosphorylated species.
14 C-PAPC was from Perkin Elmer (Cat. NEC-765). Purified water was prepared with a Milli-Q system (Millipore). [5,6,8,9,11,12,14, Preparation of cPLA 2 α -Full-length wild type and mutant forms of human cPLA 2 α containing the affinity peptide YHHHHHH fused to the C-terminal Ala-749 were prepared by a modification of the procedure described (38) (Supplemental Information). cPLA 2 α concentrations were determined from the absorbance at 280 nm (ε 280 = 0.827 mg -1 mL (38)). Mutagenesis of the coding region in the baculovirus transfer plasmid was carried out first by deletion of the desired region and then by insertion of the mutated region. Both steps were carried out using the QuickChange kit (Strategene). Full coding regions were sequenced to verify the products.
Preparation of dephosphorylated cPLA 2 α -Purified recombinant cPLA 2 α was dephosphorylated with potato acid phosphatase (PAP) by a modification of the published procedure (24) (Supplemental Information). cPLA 2 α-PAP was shown by phosphoamino analysis to lack phosphoserine (Supplemental Information).
Preparation of phosphorylated forms of cPLA 2 α -cPLA 2 α-505P and cPLA 2 α-515P were prepared by a modification of the previously reported methods (16,24) (Supplemental Information). cPLA 2 α-505P/727P was prepared from activated platelets based on the method reported by Kramer (39) .
Full details are given as Supplemental Information along with data showing that the phosphorylated forms are stoichiometrically phosphorylated.
Vesicle Binding Assays -All phospholipids were stored in CHCl 3 in Teflon septum-lined screw cap vials under argon at -20 °C. Concentrations of phospholipids were determined by the standard phosphate assay with ammonium molybdate(VI) tetrahydrate (for PIP 2 , the weight specified by the manufacturer was used). Stock solutions of phospholipids were mixed in a polypropylene microfuge tube, and most of the solvent was removed (leaving ~50 µl) with a stream of Ar with the tube placed in a 37 °C bath. The tube was placed in a Speed-Vac concentrator under vacuum for 1-2 hr. All phospholipid mixtures used for binding studies contained 0.5 mole % Lissamine rhodamine B 1,2-dihexadecanoylsn-glycero-3-phosphoethanolamine. Vesicles were prepared by freeze-thawing the lipid suspension (typically 4-6 mM phospholipid) in 10 mM MOPS, pH 7.2, 176 mM sucrose followed by extrusion through two 0.2 micron polycarbonate membranes (VWR Cat. 110606) using a LiposoFast device (Avestin) as described previously (40) . A small aliquot of lipid suspension prior to extrusion was removed for fluorimetric analysis (see below). Extruded vesicles were submitted to a pre-spin procedure (1 hr, 100,000 x g average , 21°C) in a 1.5 ml polyallomar centrifuge tube (Beckman Cat. 357448). The supernatant was removed with a pipet and discarded, and the vesicles in the pellet were resuspended by gentle mixing (gentle up and down passage with a Pipetman, 8-10 times) in buffer A (10 mM MOPS, pH 7.2, 100 mM KCl, 0.5 mM EGTA). A small aliquot of vesicles was diluted into 50 mM Tris-HCl, pH 8.0, 1% sodium cholate and submitted to fluorometry (ex 550 nm, em 590 nm). The fluorescence value was compared to that of an aliquot of the vesicle suspension prior to extrusion to calculate the percent yield of phospholipid, and this was used with the phospholipid concentrations in the original stock solutions to obtain the total phospholipid concentration of final vesicle suspension. Vesicles were used on the same day of preparation (stored at room temperature). cPLA 2 α binding reactions were prepared in 1.5 mL polyallomar microfuge tubes and contained buffer A with 0.5 mg/ml BSA containing various amounts of free calcium (see below), phospholipid (added from the calibrated, pre-spun stock in buffer A) and 50 ng of cPLA 2 α in a total volume of 1 mL. Samples were centrifuged at 100,000 x g average at 21 °C for 1 h, and two 100 µL aliquots of supernatant were submitted to duplicate radiometric cPLA 2 α assays (see below).
Buffer A containing various amounts of free calcium (0-5 µM) were prepared using EGTA/CaCl 2 mixtures and calcium-binding fluorophores as described (41) (Supplemental Information). The amount of cPLA 2 α in the supernatant above pelleted vesicles was determined using a modification of the previously reported radiometric assay (41) (Supplemental Information).
An interesting feature of adding PIP 2 to PAPC vesicles that we observed is that when the total phospholipid concentration was dropped from 200 to 25 µM, most of the PIP 2 was found in the aqueous phase above vesicles that were pelleted by ultracentrifugation (see Supplemental Information for more details). This presumably reflects the relative high aqueous phase solubility of PIP 2 compared to phospholipids that lack highly polar, phosphorylated inositol head groups.
cPLA 2 α kinetic studies -Vesicles contained 14 C-PAPC at a specific activity of 2.7 Ci/mol (made by mixing 14 C-PAPC (50 Ci/mol) with PAPC) and other phospholipids as noted. Phospholipids were mixed together as CHCl 3 solutions, and solvent was removed as described above. Buffer A was added to the dry lipid film, and vesicles were prepared by freeze-thawing followed by extrusion as described above. Extruded vesicles were diluted typically 20-fold into buffer A containing 0.5 mg/ml BSA and various concentrations of calcium (see above) to give a volume of 0.1 ml. Tubes were pre-warmed in a 37 °C bath for 5 min, and reactions were started by adding a 2 µl aliquot of enzyme stock containing 200-250 ng of cPLA 2 α (enzyme stocks were made by fresh dilution into buffer A containing 1 mg/ml BSA). Reactions were quenched after 2 min, and released 14 C-AA was measured after extraction and silica chromatography as previously described (41) .
Production of DNA constructs and recombinant adenovirus -Enhanced green fluorescent protein (EGFP)-cPLA 2 α was inserted into AdEasy vector (Qbiogene) and titered as described previously (42 Immunoblotting -For western blotting, cell lysates were prepared in ice cold buffer containing 50 mM Hepes, pH 7.4, 150 mM sodium chloride, 1.5 mM magnesium chloride, 10% glycerol, 1% Triton X-100, 1 mM EGTA and protease inhibitors. Lysates were centrifuged at 15,000 g for 10 min at 4°C and protein concentration was determined using the bicinchoninic acid reagent. Lysates were diluted in Laemmli buffer and boiled for 5 min at 100°C. Proteins were separated on 10% SDS polyacrylamide gels, transferred to nitrocellulose, and blocked for 1 h in Trisbuffered saline containing 0.25% Tween 20 and 5% nonfat dry milk. Nitrocellulose membranes were incubated overnight with a 1:5,000 dilution of antiserum to total cPLA 2 α, 1:1000 of phosphospecific cPLA 2 α antiserum, or 1:1,000 of anti-p38 or anti-pERK antibodies. Antibodies were diluted in blocking buffer. Immunoreactive protein was detected using the Amersham Biosciences anti-rabbit secondary antibody and ECL system. to tissue injury as a result of platelet aggregation. It is relevant to lung fibroblasts since it leaks into the lung during acute lung injury and contributes to fibroproliferation (46,47). Our first approach was to define the characteristics of endogenous cPLA 2 α stimulation by serum and PMA in IMLF +/+ . A time course of AA release by cPLA 2 α in IMLF +/+ was conducted. When stimulated with 10% serum, AA was rapidly released in the first 10 min then slowed through 80 min (Fig. 1A , right panel). Serum stimulated high levels of AA release that was 10% of total cell-associated radiolabeled AA at 10 min and reached 20% at 80 min. In contrast PMA stimulated a slower mobilization of AA that increased linearly through 80 min (Fig. 1A , left panel).
RESULTS
Regulation
Compared to serum, PMA stimulated much less AA release, which was less than 1% of total cell-associated radiolabeled AA at 10 min and reached 4-5% at 80 min. IMLF +/+ were stimulated with serum and PMA to determine the effect on [Ca 2+ ] i . Serum caused a rapid increase in [Ca 2+ ] i at 30 sec (Fig. 1B, panel 1 ). The initial calcium transient decreased by 60 sec, and this was followed by a sustained calcium increase characterized by low amplitude oscillations that continued for at least 30 min (data not shown). The sustained phase, but not the initial spike in calcium, was eliminated by incubation of the cells in medium containing EGTA to chelate extracellular calcium ( Activation of ERKs and p38 plays a role in regulation of cPLA 2 α-mediated AA release by many agonists in part by phosphorylation of cPLA 2 α on S505. Western blot analysis using phospho-ERK antibodies indicated that serum and PMA rapidly activated ERKs by 0.5-1 min in IMLF +/+ ( Fig.  2A) . The use of antibodies that detected total ERK protein indicated equal loading of samples (data not shown).
Serum also activated p38 (Fig. 2A) ; however no detectable activation of p38 occurred during stimulation with PMA (not shown). Additional experiments demonstrated that activation of ERKs in response to serum and PMA, and activation of p38 in response to serum, was evident up to 80 min after stimulation (data not shown).
Phosphorylation of cPLA 2 α on S505 was determined by western blotting using phosphospecific antibody (Fig. 2B ). cPLA 2 α was constitutively phosphorylated in unstimulated IMLF +/+ and phosphorylation was not significantly increased by serum or PMA. cPLA 2 α remained phosphorylated on S505 for up to 80 min in unstimulated cells and in cells treated with serum or PMA (data not shown). Phosphorylation of cPLA 2 α on S505 causes a decrease in electrophoretic mobility (gel shift) of cPLA 2 α on SDSpolyacrylamide gels (21) . In unstimulated IMLF +/+ most of cPLA 2 α was gel shifted (data not shown), consistent with results of western blots using phosphospecific antibody. This is not unexpected since we found that cPLA 2 α is constitutively phosphorylated on S505 in immortalized cells lines (27) either wild type ECFP-cPLA 2 α or the phosphorylation site mutant ECFP-cPLA 2 α-S505A. Western blots of cell lysates probed with antibody to total cPLA 2 α demonstrated that the wild type and mutant enzymes were expressed at equivalent levels ( Fig. 2C) . However, using the phosphospecific antibody, a signal for cPLA 2 α was only observed in lysates of IMLF -/-expressing wild type cPLA 2 α but not the S505A mutant confirming that the antibody is specific for cPLA 2 α phosphorylated on S505 (Fig. 2C ).
Inhibitors were used to determine if the activation of p38 and ERKs plays a role in cPLA 2 α-mediated AA release in IMLF +/+ . Inhibition of p38 by SB203580 and of MEK1 by U0126, to block ERK activation, decreased serum-induced AA release by 64% and 91%, respectively (Fig. 3A) . AA release stimulated by PMA, which does not activate p38, was not affected by SB203580 as expected. The MEK1 inhibitor blocked AA release stimulated by PMA by 83% (Fig. 3B ). The results demonstrate that the MEK1/ERK pathway regulates cPLA 2 α-mediated AA release in response to serum and PMA, and p38 contributes to the regulation of AA release in serum-stimulated cells.
In order to elucidate signaling cascades that might be involved in the activation of cPLA 2 α by serum and PMA, inhibitors of kinases implicated in cPLA 2 α activation in previous studies were employed. CaMKII regulates cPLA 2 α through a MAP kinasedependant pathway involving phosphorylation of cPLA 2 α on S515 in vascular smooth muscle cells (16, 20, 48 (Fig. 3C, 3D ). The ability of PMA to stimulate AA release implicates a role for PKC in regulating cPLA 2 α activation. To determine if PKC activation is required for serum-stimulated AA release the general PKC inhibitor GF109203X was tested. PMA activation of cPLA 2 α in IMLF +/+ was inhibited by 95% by GF109203X (Fig. 3D) . Serum stimulated AA release, however, was not significantly inhibited by blocking PKC (Fig.  3C) .
Several studies have shown that protein synthesis is required for AA release (49) (50) (51) . To determine if protein synthesis is necessary for serum-and PMA-stimulated AA release, IMLF +/+ were treated with cyclohexamide (CHX) before stimulation. CHX blocked both serum-and PMA-induced AA release by 71% and 98%, respectively, indicating that nascent protein production is needed for cPLA 2 α activation in IMLF +/+ (Fig.  3E, 3F ). CHX does not prevent translocation of cPLA 2 α to the Golgi in IMLF +/+ stimulated with serum (data not shown). IMLF +/+ were treated with the inhibitors (CHX, U0126, SB203580) that blocked AA release to determine their effect on phosphorylation of S505 or, particularly relevant for CHX, the effect on total cPLA 2 α protein levels. As shown by western blotting (Fig. 3G) , CHX had no effect on the total amount of cPLA 2 (Fig 4A, 4B) . To determine the role of extracellular calcium on AA release, IMLF -/-expressing EGFP-cPLA 2 α were incubated in medium containing EGTA. Serum-and PMA-induced AA release was blocked to near basal levels by chelating extracellular calcium (Fig. 5A) .
Since activation of the MEK1/ERK pathway is required for cPLA 2 α-mediated AA release in response to serum and PMA in IMLF +/+ , we determined if chelation of calcium by EGTA affected the activation of MAPK pathways. Western blots illustrated that chelation of extracellular calcium with EGTA does not block p38 or ERK activation (Fig 5B) .
To confirm a role for a functional C2 domain in cPLA 2 α-mediated AA release stimulated by serum and PMA, parallel cultures of IMLF -/-expressing matching amounts of wild type ECFP-cPLA 2 α and the C2 domain mutant EYFP-cPLA 2 αD43N were compared. D43 interacts with both Ca 2+ ions that bind the C2 domain and plays a critical role in mediating cPLA 2 α membrane binding (28, 52, 53) . AA release from IMLF -/-expressing the D43N mutant was significantly attenuated in response to serum and PMA indicating that calcium binding to the C2 domain is required for cPLA 2 α-mediated AA release in response to these agonists (Fig. 5C) .
Translocation of cPLA 2 α in response to serum and PMA stimulation -Live cell imaging of IMLF -/-expressing EGFP-cPLA 2 α demonstrated that translocation of cPLA 2 α to the perinuclear region occurred within seconds of serum stimulation (Fig. 6A) . In response to serum, EGFP-cPLA 2 α co-localized with the Golgi marker giantin (Fig. 6B) . Most IMLF are bi-or mutli-nucleated, a characteristic of SV40 transformation (54 6C ). There was cell to cell variation in the amount of EGFP-cPLA 2 α that dissociated from the Golgi after the initial spike in calcium subsided, but most cells showed a partial (20-30%) decrease in Golgi fluorescence by 60 sec after serum addition (Fig. 6C) . Chelating extracellular calcium with EGTA did not block the initial calcium spike induced by serum (see Fig. 1B ). However, in most cells we did not observe translocation of cPLA 2 α to Golgi when cells were incubated in medium with EGTA. In a few cells incubated with EGTA, only a transient increase in cPLA 2 α translocation to Golgi occurred and fluorescence returned to baseline by 60 sec as shown for three cells in Fig. 6D . In contrast, in cells incubated without EGTA a larger proportion of EGFP-cPLA 2 α remained associated with Golgi throughout the 160 sec time course (Fig. 6C) . In response to serum approximately 7% of the total cellular EGFP-cPLA 2 α translocated to Golgi in cells incubated without EGTA, and this decreased to 3% in the few cells that translocation was visually evident when incubated with EGTA (Fig. 6E) (Fig. 6F) .
Thus a sustained increase in [Ca 2+ ] i is required for the C2 domain-dependent translocation to Golgi and AA release in serum-stimulated IMLF.
We next investigated the effect of PMA on translocation of ECFP-cPLA 2 α. In response to PMA stimulation, ECFP-cPLA 2 α translocated to the perinuclear region (Fig.  7A) , where it co-localized with giantin at the Golgi (Fig. 7B) .
In contrast to serum, translocation of ECFP-cPLA 2 α was not detected until 8-10 min after PMA addition and reached maximal translocation approximately 15 min after stimulation ( Fig  7A, 7C) . Dual imaging of ECFP-cPLA 2 α and the C2 domain mutant EYFP-cPLA 2 αD43N co-expressed in IMLF -/-revealed little translocation of the mutant (Fig. 7C) . Collectively, the results suggest that the oscillations induced by PMA from the influx of extracellular calcium, promote the C2 domain-dependent translocation of cPLA 2 α to Golgi and AA release.
Analysis of Phosphorylation site mutants expressed in IMLF
-/--The functional role of cPLA 2 α phosphorylation was investigated by expressing wild type cPLA 2 α and phosphorylation site mutants in IMLF -/-and comparing AA release and translocation. In experiments analyzing AA release, equal expression of wild type and mutant cPLA 2 α was achieved by expressing three dilutions of adenovirus in neighboring wells. AA release experiments were conducted on all wells, and western blotting was used to determine the relative expression level of cPLA 2 α in each well for comparison of mutant and wild type cPLA 2 α. IMLF -/-expressing EYFPcPLA 2 αS505A showed a 38% decrease in AA release in response to serum compared to IMLF -/-expressing wild type ECFP-cPLA 2 α (Fig.  8A) . Analysis of cPLA 2 α phosphorylation in several cell lines has revealed that phosphorylation of S505 occurs with phosphorylation of S727 (13, 17, 18) . Therefore the ability of EYFP-cPLA 2 αS727A and EYFP-cPLA 2 αS505A/S727A to release AA was tested. AA release from IMLF -/-expressing EYFP-cPLA 2 αS727A was not significantly different from IMLF -/-expressing wild type ECFP-cPLA 2 α (Fig. 8A) . Equal expression of wild type cPLA 2 α and the phosphorylation site mutant was confirmed by western blotting (Fig. 8A, inset) . IMLF -/-expressing EYFP-cPLA 2 αS505A/S727A released approximately 50% less AA than IMLF -/-expressing equivalent levels of wild type ECFP-cPLA 2 α at both 10 and 20 min post-stimulation by serum (Fig. 8B) . AA release from IMLF -/-expressing the S505A or S505A/S727A mutants was not reduced to the extent observed using the MEK1 inhibitor, U0126 (see Fig. 3A ). This observation is consistent with our previous studies suggesting that ERKs also play a role in regulating cPLA 2 α-mediated AA release by a mechanism independent of phosphorylation on S505 (27, 49) . This was confirmed by data showing that U0126 inhibited the residual AA release from IMLF -/-expressing EYFPcPLA 2 αS505A/S727A by approximately 51% (average of 2 experiments) (data not shown).
AA release in IMLF -/-expressing the EYFP-cPLA 2 αS515A mutant was similar to wild type, and IMLF -/-expressing EYFPcPLA 2 αS515A/S505A/S727A was similar to EYFP-cPLA 2 αS505A/S727A, suggesting no role for S515 phosphorylation for serumstimulated AA release (data not shown). This is consistent with the lack of affect of the CAMKII inhibitor, KN93 on AA release in IMLF +/+ (see Fig. 3C ). Dual imaging was used to directly compare translocation of wild type ECFPcPLA 2 α co-expressed with either EYFPcPLA 2 αS505A/S727A (Fig. 8C) or EYFPcPLA 2 αS505A in IMLF -/- (Fig. 8D) . The initial rate of translocation of wild type ECFP-cPLA 2 α and EYFP-cPLA 2 αS505A/S727A or EYFP-cPLA 2 αS505A to Golgi in response to serum was similar for the first 30 sec. After this time wild type ECFP-cPLA 2 α did not accumulate further on the Golgi and began to slowly dissociate from the Golgi in most cells (Fig. 8C & 8D) .
However, EYFPcPLA 2 αS505A/S727A and EYFPcPLA 2 αS505A continued to accumulate on Golgi over the next 1-2 min. We also compared the function of wild type cPLA 2 α and the phosphorylation site mutants in IMLF -/-stimulated with PMA. The release of AA in response to PMA by IMLF -/-expressing EYFP-cPLA 2 αS505A (Fig. 8E) or EYFPcPLA 2 αS505A/S727A (Fig. 8F ) was blunted by 30% compared to cells expressing wild type ECFP-cPLA 2 α. The results demonstrate that phosphorylation of cPLA 2 α at S505 augments AA release but is not essential.
Interfacial binding and kinetics of cPLA 2 and its phosphorylated forms in vitroOur results show that sub-optimal AA release by phosphorylation site mutants is not due to a defect in translocation to the Golgi or stable membrane binding in response to physiological increase in calcium induced by serum. These data are not consistent with a previous report showing that phosphorylation on S505 increases the membrane affinity of cPLA 2 α in cells and in vitro (25) . Therefore, we measured the interfacial kinetics and binding of different phosphorylated forms of cPLA 2 α in vitro. To directly measure the binding of cPLA 2 α to vesicles in vitro, we measured the amount of enzyme in the supernatant above vesicles that were pelleted using ultracentrifugation (vesicles were loaded with sucrose to allow them to pellet). As shown in Fig. 9A , the amount of dephosphorylated cPLA 2 α (cPLA 2 α-PAP) bound to PAPC vesicles increases as the concentration of free Ca 2+ increased from 0 to 22 µM. A concentration of PAPC of 200 µM was used, which approximates the estimated concentration of phospholipid that cPLA 2 α encounters inside of mammalian cells (55) . The buffer was chosen to give physiological pH and ionic strength. Centrifugation studies carried out in the absence of vesicles showed no loss of cPLA 2 α-PAP from the buffer solution at all concentrations of Ca 2+ ( Supplementary Fig. 2) ; thus, depletion of enzyme from the supernatant is the result of interfacial binding to vesicles. From the data in Fig. 9A , we obtain the concentration of calcium that allows 50% of the cPLA 2 α-PAP to bind to vesicles. We denote this value as app K Ca to reflect the fact that it is an apparent dissociation equilibrium constant that is composed of all calcium-dependent steps (56) . From the same figure we determine the fraction of enzyme bound to vesicles in the absence of Ca 2+ and the fraction of enzyme bound at saturating Ca 2+ . This interfacial binding experiment was repeated using cPLA 2 α that is stoichiometrically phosphorylated on S505 only (cPLA 2 α-505P) (Fig. 9A ) or on S515 (cPLA 2 α-515P) (Supplemental Fig. 3) . Results for all enzyme forms are summarized in Table 1 (Table 1) .
We also determined the Ca 2+ dependence of hydrolysis of 200 µM 14 C-PAPC vesicles by phosphorylated forms of cPLA 2 α. As shown in Supplemental Fig. 4 , the amount of 14 C-arachidonate released from 14 C-PAPC vesicles rises steadily from 0-30 min; thus, studies carried out by quenching the reaction after a 2 min incubation provide the initial reaction velocity. As shown in Fig. 9B (33, 37) . Basic residues K488, K543, K544 in cPLA 2 α were mutated to asparagines to determine their role in regulating cPLA 2 α. AA release from IMLF -/-expressing the EYFP-cPLA 2 αK488N/K543N/K544N triple mutant was decreased by 78%, compared to cells expressing an equivalent amount of wild type ECFP-cPLA 2 α in response to serum (Fig.   10A ). In contrast there was no significant decrease in AA release from IMLF -/-expressing the triple mutant in response to PMA (Fig. 10B) . Live cell imaging showed a similar initial rate of translocation of EYFPcPLA 2 αK488N/K543N/K544N and wild type ECFP-cPLA 2 α in response to serum, but the mutant exhibited an increase in Golgi binding after the first 30 sec (Fig. 10C ). The results demonstrate that the decreased AA release by the basic residue mutant does not correlate with a defect in translocation.
Effect of PIP 2 on the interfacial properties of cPLA 2 α in vitro -As a correlate to the cellular experiments, we studied the effect of PIP 2 on interfacial binding and kinetics of wild type cPLA 2 α and cPLA 2 α containing mutations in basic residues in the catalytic domain. The role of phosphorylation on cPLA 2 α activation by PIP 2 was also investigated. The results are summarized in Tables 1 and 2 (binding and kinetic Interfacial kinetic studies summarized in Table 2 show that inclusion of 10 mole % PIP 2 in PAPC vesicles led to a ~5-fold increase in the specific activity of cPLA 2 α-PAP and all of its phosphorylated forms in the presence of saturating Ca We also studied cPLA 2 α mutants in which basic residues possibly involved in interaction with PIP 2 were mutated to asparagine. Enzyme activity data versus the concentration of Ca 2+ for cPLA 2 α-PAP-K488N/K543N/K544N and cPLA 2 α-PAP-K271N/K273N/R274N are summarized in Table 2 (kinetic curves are shown in Supplemental  Fig.  8 ). cPLA 2 α-PAP-K488N/K543N/K544N showed an ~2-fold increase in specific activity compared to wild type enzyme on PAPC vesicles, and the mutant did not show rate enhancement when 10 mole % PIP 2 was added to PAPC vesicles (virtually identical results were obtained with cPLA 2 α-PAP-K541N/K543N/K544N, a second triple site mutant involving basic residues occupying a similar region of the enzyme's surface, data not shown). The mutant cPLA 2 α-PAP-K271N/K273N/R274N displayed the same activity as wild type enzyme on PAPC vesicles, and showed a rate enhancement by 10 mole% PIP 2 about half of that seen for wild type enzyme. Values of app K Ca for all mutants were similar to those for wild type enzymes with both PAPC and PAPC/PIP 2 vesicles ( Table 2 ). The results of the in vitro experiments support the cellular studies and implicate a role for the basic residues in the catalytic domain of cPLA 2 α in regulating hydrolytic activity through interaction with anionic phospholipids and not by enhancing calcium-dependent membrane binding.
DISCUSSION
cPLA 2 α activity is controlled by complex posttranslational mechanisms. The importance of lipid mediators produced as a result of cPLA 2 α activation necessitates tight multidimensional regulation (6 2 α. In contrast to physiological agonists such as serum, calcium ionophores used at concentrations that induce a high, sustained influx of calcium promote translocation of a much larger proportion of cPLA 2 α to membrane (10). As we previously reported, the release of calcium from intracellular stores promotes more rapid translocation of cPLA 2 α to Golgi than does influx of extracellular calcium suggesting the importance of local high calcium increases released from intracellular membrane stores for rapid translocation (10, 34) . Chelating extracellular calcium did not block the initial increase in [Ca 2+ ] i induced by serum but prevented AA release. Translocation of cPLA 2 α to Golgi in response to serum was only briefly evident in a few cells when incubated in medium containing EGTA. This indicates that the influx of extracellular calcium triggered by store depletion is required to promote stable binding of cPLA 2 α to membrane, which is necessary for mediating AA release. This is consistent with previous reports demonstrating the important role for capacitative calcium influx and the duration of calcium elevation in regulating cPLA 2 α-mediated AA release (59) (60) (61) . Thus, the two phases of calcium mobilization induced by serum serve to induce rapid and stable binding of cPLA 2 α to membrane.
We also demonstrate that the low amplitude sustained calcium oscillations induced by PMA promote translocation of cPLA 2 α in the absence of a rapid calcium transient from intracellular stores. This occurs more slowly, taking several minutes for cPLA 2 α to accumulate on the Golgi. There was considerable variation in the extent of cPLA 2 α translocation in cells stimulated with PMA, reflecting the cell-to-cell variability in the extent of PMA-induced [Ca 2+ ] i oscillations. In contrast to PMA-stimulated cells, translocation of cPLA 2 α was evident in over 90% of the serum-stimulated cells. Also, serum stimulates a greater proportion of cellular cPLA 2 α to translocate to Golgi due to the rapid high amplitude release of calcium from intracellular stores. This may account for the higher levels of AA release induced by serum compared to PMA.
Previous studies identified a role for CaMKII activation and phosphorylation of cPLA 2 α on S515 in regulating AA release in smooth muscle cells stimulated with norepinephrine (16, 20, 48) . However, we found no evidence for this pathway in regulating AA release in IMLF +/+ . The CaMKII inhibitor had no effect on AA release from IMLF +/+ , and AA release from IMLF -/-expressing the S515A mutant was the same as cells expressing wild type cPLA 2 α. Therefore the regulation of cPLA 2 α by CaMKII is cell type specific. We could not demonstrate a change in specific activity or app K Ca after stoichiometric phosphorylation of cPLA 2 α-PAP on S515 by CaMKII. In a previous study it was shown that treatment of cPLA 2 α with CaMKII in vitro led to a 2-to 3-fold increase in specific activity (16) . The reason for this discrepancy is not known. Therefore it remains unclear how phosphorylation of cPLA 2 α on S515 in cells functions to regulate cPLA 2 α especially since it has been shown that phosphorylation of S515 or S505 does not regulate cPLA 2 α translocation in smooth muscle cells stimulated with norepinephrine (20) .
Serum-and PMA-stimulated AA release is dependent on activation of MAPKs in IMLF +/+ as observed in many cell types (1). Activation of MAPKs by serum and PMA was not blocked by extracellular EGTA indicting that it is not dependent on the influx of calcium. cPLA 2 α is constitutively phosphorylated on S505 in IMLF -/-, as we have observed in other cells lines (personal communication) (27) . This may be a consequence of culturing cells in the presence of serum, which activates MAPKs resulting in cPLA 2 α phosphorylation. We found that after overnight serum starvation, a protocol commonly used to quiesce cells, MAPKs exhibit only weak activation and can be strongly activated upon subsequent serum addition.
However, cPLA 2 α remains phosphorylated on S505 during serum starvation indicating that phosphorylation at S505 is very stable. This is consistent with our previous data in macrophages showing that activation of ERKs in response to CSF-1 is very transient but leads to stable phosphorylation of cPLA 2 α on S505 (22) . Our results in IMLF also confirm that phosphorylation on S505 is not sufficient for cPLA 2 α to mediate AA release which requires an increase in [Ca 2+ ] i for translocation to membrane. Although MAPKs play a role in regulating cPLA 2 α by phosphorylation of S505, they clearly play an additional novel role in regulating cPLA 2 α since agonistinduced AA release is blocked by MAPK inhibitors without affecting S505 phosphorylation. We have previously made this observation in other cell types suggesting that it is a commonly used regulatory pathway although the mechanism involved remains to be determined.
Phosphorylation of cPLA 2 α on S505 enhances its activity in vitro and its ability to release AA in cells (14, 15, 17, 24) . We found that IMLF -/-expressing EYFP-cPLA 2 α-S505A released approximately 38% less AA than cells expressing wild type ECFP-cPLA 2 α indicating that phosphorylation on S505 augments AA release but is not essential in IMLF. AA release in IMLF -/-expressing the double phosphorylation site mutant S505A/S727A was attenuated to a similar extent (50%).
A comparison of the translocation properties of wild type ECFPcPLA 2 α and the double EYFP-cPLA 2 α-S505A/S727A and single EYFP-cPLA 2 α-S505A phosphorylation site mutants showed similar initial rates of translocation of the mutants to Golgi in response to serum as wild type cPLA 2 α that correlated with the initial rise in [Ca 2+ ] i . The phosphorylation site mutants tended to accumulate on Golgi to a greater extent than wild type cPLA 2 α. The reason for this is not known but despite greater levels of the mutants on Golgi their ability to release AA is not as efficient as wild type cPLA 2 α. Our data demonstrate that phosphorylation on S505 does not augment translocation of cPLA 2 α in response to a capacitative calcium increase (serum stimulation) or in response to a low oscillatory rise (PMA stimulation) that is not preceded by a high amplitude transient increase in calcium from intracellular stores. Thus we find no evidence that phosphorylation on S505 affects the calcium-dependent membrane binding affinity of cPLA 2 α.
We found that mutating the phosphorylation site S727 to alanine did not affect cPLA 2 α translocation or AA release in cells. Also, S727 phosphorylation did not influence cPLA 2 α binding or catalytic activity in vitro.
Unlike the role of S505 phosphorylation in enhancing cPLA 2 α catalytic activity, a recent study has identified a novel function for S727 phosphorylation in regulating protein-protein interactions (62) . Previous studies had identified a cPLA 2 α binding protein, p11 (also called S100-A10 or calpactin I light chain) that forms a complex with annexin A2 in cells (63, 64) . p11 was reported to bind to the catalytic domain of cPLA 2 α and inhibit its activity (63) . A recent study found that the p11-annexin A2 complex binds to the hydroxyl group of S727 and prevents binding of cPLA 2 α to membrane (62) . The interaction of cPLA 2 α with the p11-annexin A2 complex is disrupted by phosphorylation of cPLA 2 α on S727 thus relieving inhibition. Mutating S727 to alanine also disrupts interaction of cPLA 2 α with the p11-annexin A2 complex and mimics phosphorylation of S727 (62) . Our results showing that cPLA 2 α-S727A behaves similar to wild type cPLA 2 α when expressed in IMLF -/-suggests that wild type cPLA 2 α is constitutively phosphorylated on S727 (as observed for S505) or phosphorylated on S727 in response to serum and PMA, and relieved from potential inhibition by endogenous p11.
Our findings do not corroborate a report suggesting that phosphorylation of cPLA 2 α on S505 increases the membrane binding affinity of cPLA 2 α particularly at low calcium concentrations induced by adding ionomycin (25) . The reasons for the different findings are not known. However, our results in IMLF -/-correlate well with results of our in vitro experiments. Phosphorylation of cPLA 2 α at S505 and at S505/S727 (from platelets) leads to a 2-fold increase in the specific activity of the enzyme acting on PAPC vesicles, which is in line with the level of activation reported previously (for example (24, 39) . We see no evidence that phosphorylation of cPLA 2 α at S505 dramatically alters the concentration of Ca 2+ needed to support interfacial binding. It has been reported that the K d for the nonphosphorylated S505A mutant of cPLA 2 α is ~60-fold lower than that for wild type cPLA 2 α purified from Sf9 cells (which they show is mainly phosphorylated on S505) or the S505E mutant which is suggested to be a mimic of S505 phosphorylated cPLA 2 α (25). Even if we use the same vesicles and buffer reported in this previous study, we fail to see a significant effect of cPLA 2 α phosphorylation on the amount of calcium required to support interfacial binding.
The basis for this discrepancy between the two studies is not known. are close in magnitude to those reported in the earlier study (25) . Phosphorylation of cPLA 2 α has been suggested to influence the conformation of the cPLA 2 α catalytic domain on the membrane for optimal interaction with phospholipid substrate thus augmenting hydrolytic activity of cPLA 2 α (65). Conformational effects may also be the basis for enhanced activity of cPLA 2 α by interaction of the basic residues (K488/K541/K543/K544) in the catalytic domain with PIP 2 (33) . We found that addition of PIP 2 (10 mole%) to PAPC (200 µM) resulted in a 4-fold decrease in app K Ca and ~8-fold increase in the maximal activity of wild type cPLA 2 α in the presence of saturating calcium but did not activate cPLA 2 α-K488N/K543N/K544N. Our results are more in line with data showing from 3.5-to 8-fold stimulation of cPLA 2 α activity with PIP 2 using PC vesicles (33, 35) , and not the 120-fold increase observed using PC/Triton X-100 mixed micelles (36) . In the absence of calcium, we found that PIP 2 did not change the amount of cPLA 2 α catalytic activity, which remained low at about 7-10%, or the amount of cPLA 2 α bound to vesicles. It has been reported that the inclusion of PIP 2 in PAPC/Triton X-100 mixed micelles substrate allows the enzyme to act in a calciumindependent manner and yet the enzyme showed no activity in the absence of calcium when PIP 2 was omitted from mixed micelles (36, 37) . Since it is thought that the main role of calcium is to allow interfacial binding of cPLA 2 α, this result would suggest that PIP 2 allows the enzyme to bind to PAPC/Triton X-100 mixed-micelles with similar affinity in the presence and absence of calcium. It is clear from results of our work and a previous study that calcium-independent activation of cPLA 2 α by PIP 2 does not occur with phosphatidylcholine liposomes (33) . This suggests that with an aggregate that is predominantly composed of a neutral detergent, Triton X-100, and only a small amount of PAPC, small amounts of anionic phospholipid such as PIP 2 ] i increase. Surprisingly, the triple mutant accumulated on Golgi to a greater extent than wild type cPLA 2 α. This may explain our results and a previous report that the basic residue mutant has ~2-fold greater activity in vitro using PC vesicles (33) . The cellular data suggest that interaction of the basic residues with anionic components on the membrane regulates catalytic activity and not calcium-dependent membrane binding, consistent with our in vitro experiments. The cell results do not establish that PIP 2 is the endogenous component in membranes that activates cPLA 2 α nor does it establish whether the component is constitutively present or rapidly increased in response to serum. It has not been confirmed that PIP 2 is the endogenous activator of cPLA 2 α in cells. It has recently been demonstrated that cPLA 2 α-mediated AA release is stimulated when intracellular levels of polyphosphoinositides are increased by feeding cells either PI-4,5-P 2 or PI-3,5-P 2 suggesting that the response is not specific to PI-4,5-P 2 , but again this does not establish that phosphorylated phosphatidylinositol is the endogenous activator of cPLA 2 α (66). cPLA 2 α preferentially targets Golgi, which contains very low levels of PI-4,5-P 2 compared to the plasma membrane (67) . A role for other anionic lipids or binding proteins in regulating cPLA 2 α through interaction with basic residues in the catalytic domain remains a possibility. We found that blocking nascent protein synthesis using CHX diminished cPLA 2 α-mediated AA release in IMLF +/+ supporting previous reports that an unidentified, rapidly turning over protein aids in cPLA 2 α-mediated AA release (49-51). CHX did not block calcium mobilization or translocation of cPLA 2 α to Golgi suggesting that the rapidly turning over protein plays a role in enhancing cPLA 2 α activity once it has translocated to membrane.
In summary, our ability to reconstitute IMLF lacking endogenous cPLA 2 α with wild type and mutant forms of functionally active, fluorescent protein-tagged cPLA 2 α allowed us to directly compare for the first time translocation and AA release in response to the physiological agonist serum in the absence of endogenous wild type cPLA 2 α. The results demonstrate that phosphorylation of cPLA 2 α and the interaction of basic residues in the catalytic domain with membrane components largely act to regulate catalytic activity and not calcium-dependent membrane binding.
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The abbreviations used are: PLA 2 , phospholipase A 2 ; cPLA 2 , cytosolic PLA 2 ; PAPC, 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine; cPLA 2 α-505P, cPLA 2 α phosphorylated at S505, likewise for cPLA 2 α-505P/727P and cPLA 2 α-515P; PAP, potato acid phosphatase; cPLA 2 α-PAP, cPLA 2 expressing EGFP-cPLA 2 α were incubated in media containing EGTA and then images were collected using a FITC filter after stimulation with serum (arrow). (E) Translocation data from (C) and (D) were analyzed to determine the % of EGFP-cPLA 2 α bound to Golgi at the peak of serum-induced translocation (~30 sec) in cells incubated with and without extracellular EGTA. Translocation data was calculated based on average fluorescence intensity of EGFP-cPLA 2 α on the Golgi in each cell. Values were corrected for background fluorescence and differential bleaching at each wavelength through the duration of the imaging, and expressed relative to time zero (F T /F 0 ). Calcium ratios (F403/F470) were calculated and corrected for background fluorescence and expressed relative to time zero (R T /R 0 ). Graphs are representative of 10 cells from three independent experiments. (F) IMLF -/-co-expressing ECFP-cPLA 2 α and EYFPcPLA 2 αD43N were stimulated with serum and translocation was determined as described in (A).
Data is presented relative to time zero (F T /F 0 ). The graph is representative of 15 cells from three independent experiments. 3 H]AA by the mutant was significantly less (p<0.05) than by wild type cPLA 2 α as indicated (*). Cell lysates were made from each well and immunoblotting for cPLA 2 α was conducted to determine expression levels (inset) of wild type and mutant cPLA 2 α in each well. (C) IMLF -/-co-expressing wild type ECFP-cPLA 2 α and EYFP-cPLA 2 αK488N/K543N/K544N were stimulated with serum and images were collected using both a CFP and YFP filter and a 40X oil immersion objective. Translocation data was calculated based on average fluorescence intensity of a mask of the Golgi in each cell. Values were calculated by subtracting background fluorescence and correcting for differential bleaching at each wavelength throughout the imaging. Data is presented relative to time zero (F T /F 0 ). Data is representative of 10 individual cells from 3 independent experiments.
